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Extreme swing of phosphor from severe hyperphosphatemia to severe hypophosphatemia in a patient with blast
crisis of myeloid origin was the result of imbalance between massive apoptosis of leukemic cells in the context of
spontaneous tumor lysis syndrome and massive production of leukemic cells with only 1% of blast in peripheral
blood. The mutated p53 protein suggested acting as oncogene in the presented case and possibly affecting
phosphor status.
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Severe symptomatic hypophsopahatemia was reported in
a small number of case reports in patients with acute
myelomonocytic leukemia [1] with extreme white blood
count (200-380/μL) because of high phosphate demands
of dividing leukemic cells. It was also reported during
hematopoietic reconstitution after allogeneic peripheral
blood stem cell transplantation [2] due to excessive cel-
lular phosphate uptake for hematopoietic reconstitution
and in tumor genesis [1].
Leukemic blast cells of myeloid origin fail to show in-
hibition of glycolysis by oxygen [3] and causes hypopho-
sphatemia by redistribution of phosphorus to the cells,
to provide phosphate for glycolytic intermediates.
Severe hypophosphatemia may adversely affect major
organ systems including severe generalized muscle weak-
ness as observed in our patient. Reduction in the erythro-
cyte content of 2,3-diphosphoglycerate may impair
release of oxygen resulting in hypoxia [4]. On the other
hand hyperleukocytosis can cause pseudohyposphatemia,* Correspondence: ophiras@sheba.health.gov.il
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reproduction in any medium, provided the orpseudohypokalemia [5] and pseudohypoxaemia. Un-
awareness to this phenomenon can lead to incorrect and
harmful treatment.
Case presentation
An 80-year-old white Ashkenazi Jewish woman pre-
sented at hematology out-patient clinic with persistent
leukocytosis for the last 10 months. A peripheral blood
count revealed white-cell count (WBC) of 36,000/μL
with 58% neutrophils, 14% lymphocytes, 4% monocytes,
1% blasts, 2% metamyelocytes, 6% myelocytes and 10%
segments. The hemoglobin was 12gr/dL, platelet counts
476,000/μL and blood chemistry was unremarkable. Her
physical examination was normal as well as whole body
computerized tomography scanning (CT). Bone marrow
(BM) aspiration at that time was hyperplastic, enriched
with white cells with normal maturation and no blasts.
Megakaryocytes had dysplastic features with single nucl-
eous without lobulations. The BM findings were com-
patible with a myeloproliferative disorder with some
dysplastic changes. Cytogenetic analysis revealed 47XX
in 75% of the cells with trisomy 8 (+8) detected also by
fluorescent in situ hybridization. Janus Kinase 2 gene
V617F mutation and Bcr/Abl fusion gene were not
detected.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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negative (Ph neg) chronic myelogenous leukemia (CML)
with+8. Of note that Bcr/Abl negative CML is clinically
distinct from Bcr/Abl positive CML, myelodysplastic
syndrome and chronic myelomonocytic leukemia [6]
and usually, is associated with poor prognosis [7,8]. One
could argue whether atypical CML, Bcr/Abl negative
according to WHO classification could represent
chronic neutrophilic leukemia as in the presented case.
A year and a half after diagnosis of Phneg CML was
established, the patient complained of persistent discom-
fort and pain in the upper left abdomen lasting three
days without fever. Laboratory work-up showed creatin-
ine of 1.9 mg/dL, uric acid 13.5 mg/dL, phosphor
5.9 mg/dL, potassium 4.8 meq/L and LDH 403 IU/L.
White blood cell were 38,000/ μL with 76% neutrophils,
7% lymphocytes, 17% monocytes , 1% blasts, 4% meta-
myelocytes, 10% myelocytes and 9% segments. The
hemoglobin was 10 gr/dL and platelet count was 243 k/
μL. Abdominal ultrasound (US) Doppler revealed
splenomegaly with several peripheral hypoechogenic
areas compatible with spleen infarcts (Figure 1a). Also, a
small calculus in lower calices of left kidney was noted.
Abdominal CT scan demonstrated few peripheral hypo-

































Figure 1 a: Grey scale image of ultrasound of the spleen demonstrate
(short arrow). b: Non enhanced CT image of the spleen demonstrate hyp
Level of phosphor in peripheral blood in correlation to white cell counts. T
is demonstrated.No enlargement of retroperitoneal lymph nodes or bulky
mass was observed.
A month earlier, the patient went through colonoscopy
and a villous adenoma polyp was found. Urianalysis of
sediment revealed amorphous urates and 30 erythro-
cytes/ high-power field (HPF).
A rise in creatinine at the time of presentation from
0.65 to 1.9 mg/dL, uric acid up to 13.5 mg/dL, phos-
phate up to 5.9 with calcium 9.6 mg/dL, LDH 403 IU/L
and alkaline phosphatase 57 IU/L support a diagnosis of
acute urate nephropathy. The latter is the outcome of
precipitation of uric acid in distal tubules and collecting
ducts because of increased filtered load of urate due to
excessive production of purines as occurs in tumor lysis
syndrome (TLS) [9]. TLS can occur spontaneously [10],
but it is commonly seen following the initiation of anti-
cancer treatment [9]. It occurs in both hematological
malignancies and in solid tumors, which harbor high
proliferative rates and tumor burden.
The patient's creatinine continued to rise, and the
phosphor reached a value of 9.6 mg/dL. At that point
the patient was started on hemodialysis and received 5
treatments, before further deterioration occurred. The
patient was also treated with aluminum hydroxide
























small peripheral hypo echoic area compatible with infarcts
odense peripheral areas compatible with splenic infarcts (arrow). c:
he extreme shift from hyperhsophatemia to severe hypophsphatemia
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when neither chemotherapy nor biological agents or
steroids were administered. Furthermore, there was no
evidence of a bulky disease. Patient's counts remained
stable. Although the patient's ultrasound study revealed
a kidney stone, there was no evidence of any ureteral ob-
struction to explain the onset of renal failure. The use of
oral sodium phosphate solution preparations for bowel
preparation before colonoscopy could cause acute renal
failure because of high phosphorus content that poten-
tially can cause chronic kidney damage [11] but she was
not treated with phosphate based preparations and the
hyperphosphatemia developed a month after the proced-
ure. One should also consider renal infarcts in the differ-
ential diagnosis of the patient's renal failure taking also
into account the assumption of spleen infarcts by US
and CT scan. However kidney infarcts were ruled out
using dynamic and static kidney scintigraphy with Tc-
99 M-DTPA. Doppler US of renal arteries ruled out
other renal arterial pathology.
At this point, monocytosis in peripheral blood counts
became significant and anemia was evident. Histopath-
ology of the BM showed hypercellularity with sheets of
immature-looking cells comprising at least 90% of the BM
spaces. The red cell line and the megakaryocytes were in-
conspicuous. Extensive apoptosis of the cells with phago-
cytosis and a “starry sky” appearance, reminding Burkitt’s-
like lymphoma was a prominent feature (Figure 2, a+b).
On immunostains, the immature-looking cells were posi-
tive for myeloperoxidase and negative for CD20, CD3,Figure 2 a. The white areas represent extreme apoptosis of the leuke
to these areas (arrow), viable and proliferating leukemic cells are present (H
leukemic cells. Mitotic figures are indicated by arrows (H&E, 60x10). c. Norm
immunostain, 60x10). d. Bone marrow with AML as negative control (p53 p
disintegrated areas, indicated by arrows, are negative (p53 phosphor-specif
are positive. See arrows (p53 phosphor-specific antibody immunostain, 60xCD10, BCL6, BCL1, Tdt and CD34. The CD68 indicated
the presence of numerous histiocytes, but the immature-
looking cells were negative. Immunophenotyping of BM
disclosed 21% blasts in the blast gate with features of mye-
loblast/monoblast (HLADR, CD14, CD33, and CD64).
None of the cells were CD34 positive. According to the
morphological and phenotypical features the diagnosis of
myelomonoblastic leukemia was made. The patient was
treated with hydroxyurea for 5 days only until further de-
terioration occurred.
Constitutional activation of the MYC proto-oncogene
resulting from a t(8;14) has been demonstrated in ap-
proximately 80% of patients with Burkitt lymphoma, but
only in two cases with acute myeloid leukemia (AML)
[12]. Search for t(8;14)/cMyc was negative albeit the
histology appearance of "starry sky". Interestingly +8
which is among the commonest genetic aberrations
(70%) seen in AML [13] declined from 90% to 24% sug-
gesting the emergence of a different clone at the time of
transformation into acute leukemia.
The acute myelomonocytic leukemia that developed
in our patient might explain the relative hypokalemia
in spite of tumor lysis and renal failure. Hypokalemia
is known to develop in patients with acute monoblas-
tic leukemia and significantly correlates with hyper-
leukocytosis , increased blood and urine lysozyme.
The lack of hyperkalemia initially raised questions
regarding the diagnosis of TLS and prompted the
aforementioned investigation for other etiologies of
renal failure.mic cells, up to disintegration of the tissue (short arrows). Right
&E, 20x10). b. Higher magnification of viable and proliferating
al bone marrow as negative control (p53 phosphor-specific antibody
hosphor-specific antibody immunostain, 60x10). e. The apoptotic and
ic antibody immunostain, 60x10). f. The viable and proliferating areas
10).
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and fatigue which led to diagnosis of severe hypopho-
sphatemia <0.5 mg% (Figure 1c) while potassium
remained in normal level despite the presence of pro-
gressive renal failure. Other test results revealed: serum
calcium between 10.6-11.2 mg%, venous pH 7.38, venous
lactate levels mostly within normal limits except for one
elevated measurement of 30 mg% (N 6-18 mg%).
Aluminum hydroxide was stopped and the patient was
treated with IV KPO4 with no significant improvement.
Several potential causes that could contribute to hypo-
phosphatemia in our patient were ruled out, such as nu-
tritional causes, antacids ingestion, sepsis or diabetic
ketoacidosis. Urine output was low, and parathyroid hor-
mone and 1,25(OH)2 dihydroxyvitamin D levels were
within normal limits, thereby excluding overt hyperpara-
thyroidism and oncogenic hypophosphatemic osteomal-
acia even though, urine phosphor levels were not
measured.
In addition the patient was also never treated with
chemotherapeutic agents beside hydroxyurea or thyro-
sine kinase inhibitor such as imatinib, known to cause
mild hypophosphatemia (around 2 mg%), possibly
through inhibition of bone turnover, which in turn, trig-
gered a secondary hyperparathyroidism in an attempt to
maintain calcium homeostasis [14]. Another suggested
mechanism is depletion of intracellular phosphate in
renal tubular cells, potentially interfering with reabsorp-
tion of urinary phosphate [15].
In our patient the shift of phosphor from severe hyper-
phosphatemia of 9.6 mg/dL to <0.5 mg/dL phosphor six
days later even when WBC counts solely tripled in num-
ber (Figure 1c) and analysis of blood phosphor was done
immediately in a patient with end stage renal failure was
the warning sign of the arrival of fulminant and aggres-
sive leukemia without more than 1% of blasts of periph-
eral WBC at that time of demise.
The presence of massive apoptosis was noted aside to
tumor genesis in the patient's BM (Figure 2) and it is
conceivable that the phosphor that is released during
apoptosis is reuptaken by cells for tumor genesis,
explaining the extreme change in phosphor level up to
severe hypophosphatemia in our patient. Therefore, we
determined to assess whether the missing phosphor
could be seen in patient's BM specimen. Although there
is no technique quantifying free phosphor but in serum,
we tried to asses intracellular phosphor content via
immunohistochemical stain. We chose p53 phosphor-
specific antibody (clone EP42Y, Burlingame, California)
due to the fact that in the presence of wild P53 protein,
tumor cells will usually go into apoptosis in contrast to
mutated P53 protein where it can act as oncogene thus
promoting tumor genesis [16]. The unmutated p53 pro-
tein, when phosphorylated on serine-46 site (pS46),becomes a stabilized and activated proapoptotic protein,
induced by DNA-damage. But the p53 phosphor-specific
antibody that we used stained negative in apoptotic cells
and positive in part of the viable proliferating blasts sug-
gesting that the P53 was mutated (Figure 2).
Conclusions
The presented case demonstrates the extreme shift from
severe hyperphsosphatemia to severe hypophosphatemia
during blast crisis of a patient with Phneg CML. Hyper-
phosphatemia was due to massive apoptosis of leukemic
cells in the context of TLS and then inverted to severe
hypophosphatemia despite end stage renal failure when
tumor genesis prevailed and resulted in the patient's
death with peripheral WBC of 132,000 /uL, of those only
1% were blasts. Since neither the occurrence nor the se-
verity of this hyper-hypophosphatemic shift can be pre-
dicted from the patient’s baseline disease, and therefore
cannot be treated ahead of time, it is very important to
be aware of this possible complication, carefully follow-
up serum phosphor and provide immediate treatment
when even mild changed occur.
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